-
Mashup Score: 0
Adding pegargiminase to standard chemotherapy can improve outcomes in patients with chemotherapy-naïve, nonepithelioid pleural mesothelioma, data suggest.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 42Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma - 1 month(s) ago
This randomized clinical trial assesses the effect of pegargiminase-based chemotherapy on survival in patients with nonepithelioid pleural mesothelioma.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Social Determinants of Health Impact on Survival of Patients With Malignant Pleural Mesothelioma - 3 month(s) ago
Patients with malignant pleural mesothelioma (MPM) have a high mortality risk, even after optimal management and accounting for differences in comorbidities. We aimed to assess the overall survival of patients with operable MPM based on social determinants of health (SDH). We hypothesized that an SDH score can predict patients with poorer overall survival despite optimal management.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Mesothelioma incidence, death rates dropped between 1990 and 2019 - 3 month(s) ago
Between 1990 and 2019, global age-standardized incidence and mortality rates of mesothelioma went down, according to results published in Annals of the American Thoracic Society.“This study would be useful for policymakers to assess the burden of mesothelioma and carry out appropriate plans against this cancer and its risk factors,” Jonghoon Han, from the College of Medicine at Yonsei
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0Mesothelioma incidence, death rates dropped between 1990 and 2019 - 3 month(s) ago
Between 1990 and 2019, global age-standardized incidence and mortality rates of mesothelioma went down, according to results published in Annals of the American Thoracic Society.“This study would be useful for policymakers to assess the burden of mesothelioma and carry out appropriate plans against this cancer and its risk factors,” Jonghoon Han, from the College of Medicine at Yonsei
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 37
Mesothelioma is a rare and aggressive malignancy with a poor prognosis. Without treatment, the median survival time ranges between six and nine months [1]. As the diagnosis usually is made at an advanced stage most patients are not eligible for surgery and designated for palliative systemic treatment [2]. Treatment in first-line with a combination of platinum and pemetrexed resulted in a median survival benefit of three months [3]. The addition of bevacizumab resulted in an additional survival benefit of nearly three months [4].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Pembrolizumab plus platinum-pemetrexed chemotherapy may be a new treatment option for patients with advanced pleural mesothelioma.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Open Comment of Guidelines - 5 month(s) ago
Open comment allows for key stakeholders to critically review and identify any errors or gaps in a draft guideline prior to its finalization and publication.
Source: old-prod.asco.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Laser Assisted Extended Pleurectomy Decortication for Malignant Pleural Mesothelioma | CTSNet - 5 month(s) ago
Malignant pleural mesothelioma is an aggressive tumor of the pleura. Extended pleurectomy and decortication is a lung sparing cytoreductive procedure used in the management of this disease for curative intent. In 2011, the International Association of Society of Lung Cancer (IASLC) and International of Mesothelioma Interest Group (IMIG) described the consensus report of the definition of…
Source: ow.lyCategories: General Medicine News, Cardiac SurgeryTweet
-
Mashup Score: 1Mesothelioma: Updates in Current and Emerging Therapies - 6 month(s) ago
Can combination therapies improve outcomes for patients with mesothelioma?
Source: www.medscape.orgCategories: General Medicine News, Latest HeadlinesTweet
Adding pegargiminase to standard chemotherapy can improve outcomes in patients with chemotherapy-naïve, nonepithelioid pleural #mesothelioma. Published in @JAMAOnc. https://t.co/6kBnx26n1H